Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free ... their previous forecast of ($1.33). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock.

Find the latest Corbus Pharmaceuticals Holdings CRBP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Outperform recommendation. Analyst Price Forecast Suggests 690.09% ...

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability ...

Jefferies lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $70 and keeps a Buy rating on the shares. The firm’s ...

William Blair analyst Andy Hsieh reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today. The company’s shares opened ...

China’s Economy Faces Headwinds Amid US Tariffs and Deflation RisksThu, 13 Feb 2025 03:30:15 GMT BTC Price Forecast: US Tariffs and Fed Policy End Six-Week ETF Inflow StreakSun, 16 Feb 2025 03: ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP advanced 1.03% to $6.84 Wednesday, on what proved to be an all-around ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP shed 2.58% to $6.79 Friday, on what proved to be an all-around positive ...

Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the Earnings Calendar to see dates for upcoming earnings announcements.